SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing a notable surge driven by a significant short squeeze and a rebound in spot ETF inflows, with community members closely watching upcoming industry meetings at the White House for potential regulatory developments. While some traders are expressing optimism that this rally signals the start of a new bull cycle, others remain cautious and focused on managing risk amidst broader macroeconomic uncertainty.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna shares are surging as positive trial results for a personalized cancer vaccine, combined with established immunotherapy treatments, ignite significant market interest and trigger a massive short squeeze. Investors and the trading community are actively debating the long-term potential of this oncology breakthrough while weighing the risks of chasing such rapid volatility and substantial valuation gains.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Sellas Life Sciences is trending as investors digest major clinical news in the cancer vaccine sector, fueling speculation that similar positive outcomes could soon validate the company's own pipeline. Community discussion is dominated by hopes for a substantial valuation re-rating and potential M&A activity, while participants continue to debate the timing of imminent trial data.

Ethereum is a global, open-source platform for decentralized applications. In other words, it is a decentralized blockchain platform that enables developers to build and deploy smart contracts and applications without central authority control. Unlike Bitcoin, which primarily functions as digital currency, Ethereum operates as a programmable global computer where developers can create any type of decentralized service.   The platform hosts over $14 billion in DeFi applications with hundreds of thousands of active users across financial protocols, NFT marketplaces, and gaming platforms. Its transition to Proof of Stake in September 2022 reduced energy consumption by over 99%, addressing environmental concerns while strengthening network security.  The network operates through thousands of independent validator nodes that process transactions and execute smart contracts on the Ethereum Virtual Machine. Smart contracts are self-executing programs written in Solidity that automatically carry out agreements when conditions are met, eliminating intermediaries like banks or brokers.   Validators stake ETH as collateral to propose and validate blocks, earning rewards for honest participation while facing penalties for malicious behavior. The EIP-1559 upgrade introduced a dynamic base fee mechanism that burns ETH with each transaction, creating deflationary pressure during high network activity when more ETH is burned than issued to validators.  Vitalik Buterin proposed Ethereum in 2013, but seven co-founders helped build it, including Gavin Wood who created Solidity and the EVM technical specification, and Joseph Lubin who founded ConsenSys. The project launched in July 2015 after raising over $18 million through crowdfunding, quickly becoming the largest blockchain developer community. Major milestones include the 2020 Beacon Chain launch, the 2021 London hard fork implementing fee burning, and the 2022 Merge to Proof of Stake.   Ether (ETH) serves multiple functions: paying transaction fees (gas), staking to secure the network and earn 3-5% annual yields, serving as collateral in DeFi protocols, and purchasing NFTs and digital assets. The asset is increasingly adopted by traditional institutions, with publicly traded companies adding ETH to corporate treasuries to generate staking yields while maintaining blockchain exposure, and in 2024, the SEC approved spot Ethereum ETFs, allowing traditional investors to gain exposure through conventional brokerage accounts.  Ethereum's roadmap focuses on dramatically increasing transaction capacity to over 100,000 per second, reducing confirmation times, and enhancing decentralization while maintaining security against future threats like quantum computing.

Ethereum

Ethereum is drawing significant attention as investors speculate on a major breakout, fueled by institutional accumulation and the anticipation of regulatory catalysts following recent market volatility. Community discourse remains divided between those viewing the current consolidation as a generational buying opportunity and those cautious of further short-term downside risks.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is trending as investors react to a new regulatory filing confirming that the company sold millions of shares to bolster its cash reserves while holding its Bitcoin stash steady. The community remains deeply divided, with some bulls highlighting the potential for a short squeeze and long-term Bitcoin exposure, while vocal bears continue to criticize the company's aggressive dilution strategy and ongoing management of its preferred stock.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BitMine Immersion Technologies is trending as investors monitor ongoing share buybacks and Ethereum treasury accumulation while anticipating potential regulatory catalysts. The community remains heavily divided between long-term bulls betting on tokenization and Ethereums growth, and skeptical retail investors frustrated by the stock's long-term performance and management dilution.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending as investors react to the company's latest quarterly earnings, which highlighted raised revenue guidance and continued progress on the Sanofi COVID-19-influenza combination trial. The community remains intensely focused on the potential for strategic partnerships, with many discussing whether the company's Matrix-M platform will ultimately lead to a significant licensing deal or a full buyout.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending as market participants closely watch high-level crypto policy meetings at the White House, while the community remains polarized between those anticipating institutional adoption and critics labeling the asset a stagnating stablecoin. The price action near the dollar level has triggered significant debate among retail traders and whales over whether recent accumulation signals an upcoming breakout or a prolonged period of consolidation.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to positive updates regarding the company's BLA submission timeline and manufacturing progress for its lead prostate cancer asset, fueling speculation about potential M&A interest. The community is actively discussing the stock's robust institutional ownership, recent price momentum, and the potential for a significant valuation rerating as the company approaches key late-year clinical milestones.

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Tempus AI Inc. - Ordinary Shares - Class A

Tempus AI Inc

Tempus AI is trending as investors respond to positive Phase 3 cancer vaccine trial data involving partners like Moderna, which has invigorated sentiment across the precision medicine and biotech sectors. The community is actively discussing the stock's potential for a short squeeze given the high short interest, while balancing optimism around its long-term AI-driven healthcare platform against concerns regarding volatility and insider activity.

statis crypto Watchlist

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

eXoZymes uses AI engineered enzymes to make natural molecules outside the living cell. 
 
Chris Marlett, Chairman of the Board of eXoZymes (Nasdaq: $EXOZ ), used a May 2026 investor presentation to lay out the company’s cell free biomanufacturing platform. The platform takes the enzymes that build complex natural molecules and runs them outside the living cell, which the company says yields high purity at commercial scale and reaches molecules that are hard to extract or synthesize otherwise. 
 
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes-1 
 
Here is how Marlett described what the platform can now do: “...we are now proving that we can actually make these and scale them, which is a first, which was sort of the dream of synthetic biology but was never really delivered upon. And we’re demonstrating that we can manufacture them at scale. So many of these people are using synbio and making human gram quantities and we’re now demonstrating that we can deliver them in ton quantities. And the big benefit of what we’re doing is it’s super pure.” 
 
The presentation also covered: 
• A platform that takes enzymes out of the cell and evolves them to run at industrial scale, building on more than a decade of cell free research 
• A focus on natural molecules that are difficult to extract or synthesize through traditional methods 
• Technology transfer to a third party contract manufacturer to support scale up from lab to commercial volumes 
• The ability to engineer more potent and more bioavailable analogs of the molecules it produces 
 
Watch the full presentation: https://exozymes.twentythree.com/investor-presentation-by-chris 
 
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology that uses AI engineered enzymes to convert feedstocks into high value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. 
 
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer. 
 
$DNLI, $TWST, $DNA, $ARKG

David Shapiro

top moon

Dwight

Edward

Alfredo

Joe Downs

Bonnie Siegmund

Craig Salinas

Michael Musto

Eugene Davenport

Roberta Creech

Henry Callaghan

John Park

Melissa Vermillion

Micheal Fikes

Jeanne Hodges

James Adair

Kelly Distaffen

Renee Blankenship

Nina Studdard

Filomena Marsh

Raymond Oliver

Terry Skora

Lucy Pena

Amber Reilly

Edwina Packard

Karen Paris

Lillian Ellis

Ella Costello

Joseph Weiler

eXoZymes Inc. management brings together biotechnology and commercial expertise. The team combines scientific leadership from UCLA with business executives experienced in scaling technology companies, leveraging deep knowledge in enzyme engineering, artificial intelligence, and biomanufacturing to develop and commercialize cell-free production solutions for partners worldwide. The eXoZymes Inc.

B2idigital

eXoZymes Inc. | Nasdaq: EXOZ | B2i Digital Featured Company

eXoZymes' May 2026 investor presentation outlines the company's vision for transforming chemical manufacturing through AI-enhanced enzymes that operate outside living cells - exozymes - enabling scalable, sustainable, and highly efficient production of valuable molecules. The presentation...

TwentyThree

Investor Presentation by Chris Marlett (May 2026)

eXoZymes is redefining how complex molecules are discovered, manufactured, and commercialized. Its AI-enhanced, cell-free biomanufacturing platform turns rare, unscalable, or economically inaccessible chemistry into predictable, high-purity production. By embedding manufacturability directly into discovery, eXoZymes collapses development timelines, lowers capital intensity, and unlocks multiple commercialization paths.

Exozymes

Home - eXoZymes leading the next generation of biomanufacturing

b2i digital - connecting companies and investors through digital marketing, investor conferences, and direct introductions and meetings.

B2i Digital - Connecting companies and investors

Disclaimer - Content is provided "as is" by companies featured on the site. Conduct a trusted advisory before making investments.

Disclaimer - Consult an advisor before making any investments

StockTwits Web

eXoZymes Inc.

Denali Therapeutics Inc

Twist Bioscience Corp

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

ARK Investment Management LLC - ARK Genomic Revolution ETF

eXoZymes uses AI engineered enzymes to make natural molecules outside the living cell. 
 
Chris Marlett, Chairman of the Board of eXoZymes (Nasdaq: 

 ), used a May 2026 investor presentation to lay out the company’s cell free biomanufacturing platform. The platform takes the enzymes that build complex natural molecules and runs them outside the living cell, which the company says yields high purity at commercial scale and reaches molecules that are hard to extract or synthesize otherwise. 
 
eXoZymes Inc. is a B2i Digital Featured Company. See the company’s profile at 

 
 
Here is how Marlett described what the platform can now do: “...we are now proving that we can actually make these and scale them, which is a first, which was sort of the dream of synthetic biology but was never really delivered upon. And we’re demonstrating that we can manufacture them at scale. So many of these people are using synbio and making human gram quantities and we’re now demonstrating that we can deliver them in ton quantities. And the big benefit of what we’re doing is it’s super pure.” 
 
The presentation also covered: 
• A platform that takes enzymes out of the cell and evolves them to run at industrial scale, building on more than a decade of cell free research 
• A focus on natural molecules that are difficult to extract or synthesize through traditional methods 
• Technology transfer to a third party contract manufacturer to support scale up from lab to commercial volumes 
• The ability to engineer more potent and more bioavailable analogs of the molecules it produces 
 
Watch the full presentation: 

 
 
eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell free biomanufacturing technology that uses AI engineered enzymes to convert feedstocks into high value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at 

. 
 
Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at 

. 
 
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of EXOZ or any security, and it is not intended to offer any opinion on EXOZ as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete disclosure in the Risks and Disclosures section of 

eXoZymes Inc. is advancing a compelling approach to biomanufacturing by using AI-engineered enzymes outside the living cell, enabling the production of high-value natural compounds at commercial scale and high purity. 
 
Explore the full B2i Digital Featured Company profile to learn more about eXoZymes Inc., its technology platform, leadership team, and growth strategy at: https://b2idigital.com/exozymes-1

eXoZymes Inc. is advancing a compelling approach to biomanufacturing by using AI-engineered enzymes outside the living cell, enabling the production of high-value natural compounds at commercial scale and high purity. 
 
Explore the full B2i Digital Featured Company profile to learn more about eXoZymes Inc., its technology platform, leadership team, and growth strategy at: 